A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers

Dirk Rades; Rasmus Peuliche Vogelsang; Maxi Treder; Stefan Janssen; Steven E Schild; Niels Henrik Holländer; Ismail Gögenur

doi:10.21873/anticanres.13063

A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers

Dirk Rades, Rasmus Peuliche Vogelsang, Maxi Treder, Stefan Janssen, Steven E Schild, Niels Henrik Holländer, Ismail Gögenur

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

Background/Aim: The value of neoadjuvant radiochemotherapy for high rectal cancers is controversial. This study compared surgery plus neoadjuvant radiochemotherapy to surgery alone. Patients and Methods: Fifty-two patients with stage II/III high rectal cancers treated with surgery plus neoadjuvant radiochemotherapy were matched (1:4) to 208 patients treated with surgery alone. Matching criteria included age (≤65 vs. >65 years), gender and UICC-stage (II vs. III). These criteria were identical in all five patients used for each 1:4 matching. Both groups were compared for overall survival (OS). Results: On univariate analyses, age ≤65 years (p<0.001) was significantly associated with improved OS. A trend towards improved OS was found for neoadjuvant radiochemotherapy (p=0.078) and UICC-stage II (p=0.060). On multivariate analysis, age (p<0.001) remained significant, and neoadjuvant radiochemotherapy showed a trend towards better OS (p=0.073). Conclusion: Given the limitations of this study, the results showed that neoadjuvant radiochemotherapy may improve OS in patients with stage II/III high rectal cancers. However, these results need to be verified in a prospective randomized trial.

Original language	English
Journal	Anticancer Research
Volume	38
Issue number	12
Pages (from-to)	6877-6880
ISSN	0250-7005
DOIs	https://doi.org/10.21873/anticanres.13063
Publication status	Published - Dec 2018

Keywords

Adult
Aged
Aged, 80 and over
Case-Control Studies
Chemoradiotherapy
Combined Modality Therapy
Digestive System Surgical Procedures
Female
Humans
Male
Matched-Pair Analysis
Middle Aged
Neoadjuvant Therapy
Rectal Neoplasms/pathology
Retrospective Studies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13063

http://ar.iiarjournals.org/content/38/12/6877.full.pdf

Cite this

@article{409b733ea80c484bbc2fe676a4f9a432,

title = "A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers",

abstract = "Background/Aim: The value of neoadjuvant radiochemotherapy for high rectal cancers is controversial. This study compared surgery plus neoadjuvant radiochemotherapy to surgery alone. Patients and Methods: Fifty-two patients with stage II/III high rectal cancers treated with surgery plus neoadjuvant radiochemotherapy were matched (1:4) to 208 patients treated with surgery alone. Matching criteria included age (≤65 vs. >65 years), gender and UICC-stage (II vs. III). These criteria were identical in all five patients used for each 1:4 matching. Both groups were compared for overall survival (OS). Results: On univariate analyses, age ≤65 years (p<0.001) was significantly associated with improved OS. A trend towards improved OS was found for neoadjuvant radiochemotherapy (p=0.078) and UICC-stage II (p=0.060). On multivariate analysis, age (p<0.001) remained significant, and neoadjuvant radiochemotherapy showed a trend towards better OS (p=0.073). Conclusion: Given the limitations of this study, the results showed that neoadjuvant radiochemotherapy may improve OS in patients with stage II/III high rectal cancers. However, these results need to be verified in a prospective randomized trial.",

keywords = "Adult, Aged, Aged, 80 and over, Case-Control Studies, Chemoradiotherapy, Combined Modality Therapy, Digestive System Surgical Procedures, Female, Humans, Male, Matched-Pair Analysis, Middle Aged, Neoadjuvant Therapy, Rectal Neoplasms/pathology, Retrospective Studies",

author = "Dirk Rades and Vogelsang, {Rasmus Peuliche} and Maxi Treder and Stefan Janssen and Schild, {Steven E} and Holl{\"a}nder, {Niels Henrik} and Ismail G{\"o}genur",

year = "2018",

month = dec,

doi = "10.21873/anticanres.13063",

language = "English",

volume = "38",

pages = "6877--6880",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers

AU - Rades, Dirk

AU - Vogelsang, Rasmus Peuliche

AU - Treder, Maxi

AU - Janssen, Stefan

AU - Schild, Steven E

AU - Holländer, Niels Henrik

AU - Gögenur, Ismail

PY - 2018/12

Y1 - 2018/12

N2 - Background/Aim: The value of neoadjuvant radiochemotherapy for high rectal cancers is controversial. This study compared surgery plus neoadjuvant radiochemotherapy to surgery alone. Patients and Methods: Fifty-two patients with stage II/III high rectal cancers treated with surgery plus neoadjuvant radiochemotherapy were matched (1:4) to 208 patients treated with surgery alone. Matching criteria included age (≤65 vs. >65 years), gender and UICC-stage (II vs. III). These criteria were identical in all five patients used for each 1:4 matching. Both groups were compared for overall survival (OS). Results: On univariate analyses, age ≤65 years (p<0.001) was significantly associated with improved OS. A trend towards improved OS was found for neoadjuvant radiochemotherapy (p=0.078) and UICC-stage II (p=0.060). On multivariate analysis, age (p<0.001) remained significant, and neoadjuvant radiochemotherapy showed a trend towards better OS (p=0.073). Conclusion: Given the limitations of this study, the results showed that neoadjuvant radiochemotherapy may improve OS in patients with stage II/III high rectal cancers. However, these results need to be verified in a prospective randomized trial.

AB - Background/Aim: The value of neoadjuvant radiochemotherapy for high rectal cancers is controversial. This study compared surgery plus neoadjuvant radiochemotherapy to surgery alone. Patients and Methods: Fifty-two patients with stage II/III high rectal cancers treated with surgery plus neoadjuvant radiochemotherapy were matched (1:4) to 208 patients treated with surgery alone. Matching criteria included age (≤65 vs. >65 years), gender and UICC-stage (II vs. III). These criteria were identical in all five patients used for each 1:4 matching. Both groups were compared for overall survival (OS). Results: On univariate analyses, age ≤65 years (p<0.001) was significantly associated with improved OS. A trend towards improved OS was found for neoadjuvant radiochemotherapy (p=0.078) and UICC-stage II (p=0.060). On multivariate analysis, age (p<0.001) remained significant, and neoadjuvant radiochemotherapy showed a trend towards better OS (p=0.073). Conclusion: Given the limitations of this study, the results showed that neoadjuvant radiochemotherapy may improve OS in patients with stage II/III high rectal cancers. However, these results need to be verified in a prospective randomized trial.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Case-Control Studies

KW - Chemoradiotherapy

KW - Combined Modality Therapy

KW - Digestive System Surgical Procedures

KW - Female

KW - Humans

KW - Male

KW - Matched-Pair Analysis

KW - Middle Aged

KW - Neoadjuvant Therapy

KW - Rectal Neoplasms/pathology

KW - Retrospective Studies

U2 - 10.21873/anticanres.13063

DO - 10.21873/anticanres.13063

M3 - Journal article

C2 - 30504404

SN - 0250-7005

VL - 38

SP - 6877

EP - 6880

JO - Anticancer Research

JF - Anticancer Research

IS - 12

ER -

A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this